Pseudolaric acid B induces apoptosis in human rhabdomyosarcoma RD cells

CHUNYU LIU1,2*, FEI WANG3*, BIN WANG4*, TING WU5, YUE WANG6, WENBO HUO7, SHUXIA ZHANG7, YING SU7, JINMING LIU7, YUMENG LIU2 and JINGHUA YU1

1Institute of Virology and AIDS Research, The First Hospital of Jilin University, Jilin University, Changchun, Jilin 130021; 2Acupuncture Department, The Affiliated Hospital of Changchun University of Chinese Medicine; 3Department of Oral and Maxillofacial Surgery, Hospital of Stomatology, Jilin University, Changchun, Jilin 130000; 4Department of Infectious Diseases; 5Neonatal Intensive Care Unit, The First Hospital of Jilin University, Changchun, Jilin 130021; 6Chemistry Department of Traditional Chinese Medicine, Changchun University of Chinese Medicine; 7Department of Experimental Pharmacology and Toxicology, School of Pharmaceutical Science, Jilin University, Changchun, Jilin 130000, P.R. China

Received March 4, 2020; Accepted July 30, 2020

DOI: 10.3892/ol.2020.12222

Abstract. Pseudolaric acid B (PAB) is a diterpene-type acid isolated from the root and trunk bark of Pseudolarix kaempferi Gordon of the Pinaceae family that has been demonstrated to induce apoptosis in various cell lines and autophagy in certain cell lines including murine fibrosarcoma L929, human thyroid squamous cell carcinoma SW579 and human lung fibroblast MRC5 cells. However, in human rhabdomyosarcoma RD cells, which are derived from the most common soft tissue sarcoma in children and represent a high-grade neoplasm of a skeletal myoblast type, it is not clear whether PAB induces apoptosis or autophagy. The identification of the exact mechanism of PAB is important for studying its antitumor effects and its potential application in the treatment of human rhabdomyosarcoma. To confirm the inhibitory ability of PAB on RD cells, the inhibitory ratio of PAB was analyzed, and the results of MTT assay demonstrated that PAB inhibited RD cell proliferation. Meanwhile aggregation of the microtubule fibers was found in PAB-treated RD cells compared with that in control-treated cells, which was consistent with previous studies. In addition, PAB inhibited RD cell migration, induced apoptosis and cell cycle arrest at the G2/M phase. These results suggested that the mechanism of PAB-mediated growth inhibition in RD was similar to that reported in the human breast cancer cell line MCF-7 and the neuroglioma cell line A172; however, it was different from that reported in the L929, MRC5 and SW579 cell lines. Additional experiments demonstrated that PAB regulated the activation of caspase-8 and caspase-9 to induce apoptosis and caused an upregulation of phosphorylated H2A histone family member X and cyclin B1 expression in order to induce cell cycle arrest. Therefore, PAB may be considered a potential treatment agent for human rhabdomyosarcoma.

Introduction

Pseudolaric acid B (PAB) is a diterpene-type acid isolated from the root and trunk bark of Pseudolarix kaempferi Gordon of the Pinaceae family, also termed ‘Tu‑Jin‑Pi’ in Traditional Chinese Medicine, which has been used to treat dermatological fungal infections (1,2). PAB exerts potent inhibition of cell proliferation in vitro in various tumor cell lines by inducing cell cycle arrest and apoptosis. The major mechanisms of apoptosis include the extrinsic pathway, which activates caspase-8 and caspase-10 in response to external stimuli, and the intrinsic pathway, also termed the mitochondrial pathway, which leads to distinct morphological changes (14). The major mechanisms of apoptosis include the extrinsic pathway, which activates caspase-8 and caspase-10 in response to external stimuli, and the intrinsic pathway, also termed the mitochondrial pathway, which induces the cleavage of pro-caspase-9 in response to internal

*Contributed equally

Key words: pseudolaric acid B, apoptosis, cell cycle arrest, human rhabdomyosarcoma RD cells
stimuli (14). Autophagy is a process during which the components of the cell are delivered to lysosomes for degradation (15). Under certain circumstances, this process may promote cell death and morbidity; however, under the majority of circumstances, autophagy promotes survival by adjusting the cellular response to stress conditions (16,17). Following the induction of apoptosis or autophagy, cell cycle arrest is observed (6-8,18,19). Cell cycle arrest is a tumor-suppressive mechanism, as the cells do not enter the next phase of the retarded phase (4,7,12) and thus, cell proliferation is inhibited.

The present study aimed to prove that PAB inhibited human rhabdomyosarcoma proliferation and to confirm the inhibitory mechanism of PAB, which provided potential opportunities to further develop new drugs for improved clinical outcomes.

Materials and methods

Materials. PAB was purchased from the National Institute for the Control of Pharmaceutical and Biological Products and was dissolved in dimethyl sulfoxide (DMSO) to produce a stock solution. The DMSO concentration was maintained <0.01% in the cell culture and did not exert any detectable effect on cell proliferation or death. Propidium iodide (PI), Hoechst 33258, RNase A, 3-methyladenine (3-MA), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), monodansylcadaverine (MDC), NBT and BCIP were purchased from Sigma-Aldrich; Merck KGaA. Antibodies against Caspase-8 (cat. no. 66093-1-Ig), caspase-9 (cat. no. 66169-1-Ig), cyclin B1 (cat. no. 55004-1-AP), Beclin 1 (cat. no. 11306-1-AP), LC3 (cat. no. 14600-1-AP), beta actin (cat. no. 66009-1-Ig) and tubulin (cat. no. 10068-1-AP) were purchased from ProteinTech Group, Inc., whereas the antibody against phosphorylated H2A histone family member X (γ-H2AX; cat. no. 9718S) was purchased from Cell Signaling Technology, Inc. Alkaline Phosphatase AffiniPure Goat Anti-Mouse IgG (H+L) (cat. no. 115-055-003) and Alkaline Phosphatase AffiniPure Goat Anti-Rabbit IgG (H+L) (cat. no. 111-055-003) were obtained from Jackson ImmunoResearch Laboratories, Inc. HRP-conjugated AffiniPure Goat Anti-Mouse IgG (H+L) (cat. no. SA00001-1), HRP-conjugated AffiniPure Goat Anti-Rabbit IgG (H+L) (cat. no. SA00001-2), Fluorescein (FITC)-conjugated AffiniPure Goat Anti-Rabbit IgG (H+L) (cat. no. SA00003-2) and ECL kit (cat. no. B500014) were purchased from ProteinTech Group, Inc.

Cell culture. Human rhabdomyosarcoma RD cells (cat. no. CCL-136) were obtained from the American Type Culture Collection and cultured in DMEM (HyClone; Cytiva) supplemented with 10% fetal calf serum; 0.3% Triton X-100 was aspirated, rinsed once with PBS and cultured on the cover slips in a 6-well plate. Following 24-h culture, the cells were treated with 4 µM PAB for 24 h at 37°C, and control cells were treated with equal amount of solvent (DMSO) in 10% DMEM, then washed with PBS and fixed in 3.7% formaldehyde at room temperature for 15 min. The cells were subsequently rinsed three times in PBS. The specimens were incubated in blocking buffer (1X PBS; 5% normal cell culture fetal calf serum; 0.3% Triton X-100) for 60 min at room temperature and subsequently with the 1:300 diluted primary antibody against β-tubulin overnight at 4°C. The cells were rinsed three times with PBS and incubated with a 1:100 diluted FITC-conjugated secondary antibody for 2 h at room temperature in the dark. The secondary antibody was aspirated, rinsed once with PBS and stained with Hoechst 33258 (5 mg/l) for 30 min at room temperature. The FITC staining in three fields was visualized by fluorescence microscopy (Leica Microsystems, Inc.; magnification, x400) with an excitation wavelength of 505 nm and an emission wavelength of 534 nm. Nuclear changes were observed by fluorescence microscopy with an excitation wavelength of 350 nm and an emission wavelength of 460 nm.

Cell proliferation inhibition test. The inhibition of cell proliferation was determined by MTT assay. RD cells (1x10⁵ cells/well) were seeded into 96-well culture plates (Nalge Nunc International; Thermo Fisher Scientific, Inc.). Following 24-h culture, 0, 2, 4, 6, 8, 10, 12, 14, 16, 18 and 20 µM of PAB were added to the plates. Following incubation at 37°C for 12, 24, 36 or 48 h, respectively, cell proliferation was measured at different time points by adding 20 µl MTT (5 mg/ml) for 3 h at 37°C. DMSO (150 µl) was added to dissolve the formazan crystals. The absorbance was measured at 492 nm with an ELISA plate reader (Bio-Rad Laboratories, Inc.). The percentage of inhibition was calculated as follows: Inhibitory ratio (%) = [A₄₉₂ (control) - A₄₉₂ (sample)]/[A₄₉₂ (control) - A₄₉₂ (blank)] x100%.

Immunofluorescence assay. RD cells (5x10⁵ cells/well) were cultured on the cover slips in a 6-well plate. Following 24-h culture, the cells were treated with 4 µM PAB for 24 h at 37°C, and control cells were treated with equal amount of solvent (DMSO) in 10% DMEM, then washed with PBS and fixed in 3.7% formaldehyde at room temperature for 15 min. The cells were subsequently rinsed three times in PBS. The specimens were incubated in blocking buffer (1X PBS; 5% normal cell culture fetal calf serum; 0.3% Triton X-100) for 60 min at room temperature and subsequently with the 1:300 diluted primary antibody against β-tubulin overnight at 4°C. The cells were rinsed three times with PBS and incubated with a 1:100 diluted FITC-conjugated secondary antibody for 2 h at room temperature in the dark. The secondary antibody was aspirated, rinsed once with PBS and stained with Hoechst 33258 (5 mg/l) for 30 min at room temperature. The FITC staining in three fields was visualized by fluorescence microscopy (Leica Microsystems, Inc.; magnification, x200) with an excitation wavelength of 505 nm and an emission wavelength of 534 nm. Nuclear changes were observed by fluorescence microscopy with an excitation wavelength of 350 nm and an emission wavelength of 460 nm.

Cell migration. RD cells (5x10⁵ cells/well) in 6-well plates were cultured for 24 h, and a scratch was made randomly with 10-µl pipette tips near the center of the well, the lines with same width were chosen, and the cells were treated 4 µM PAB or equal DMSO control in DMEM culture medium with 10% fetal calf serum (7). Along the chosen line, the photograph of the wound was recorded at 0, 12, 24 and 36 h with PAB treatment by phase contrast microscopy (Leica Microsystems, Inc.; magnification, x200), respectively, and the width of wound was labeled with two parallel lines. The test was repeated three times.

Observation of morphological changes by light microscopy. RD cells (5x10⁵ cells/well) were cultured in 6 wells plates for 24 h. Subsequently, 4 µM PAB was added to the cells for 24 and 48 h, and the morphological changes in three fields were observed by phase contrast microscopy (Leica Microsystems, Inc.; magnification, x200).
mixed with 5 M NaCl (20 µl) and isopropanol (120 µl) and incubated at -20°C overnight. The samples were centrifuged at 25,000 x g for 15 min at 4°C. The supernatant was discarded, and the DNA sediment was dissolved in TE buffer (10 mM Tris-HCl, pH 7.4; 1 mM EDTA, pH 8.0) and separated by 2% agarose gel electrophoresis at 100 V for 50 min.

**Flow cytometric analysis of the cell cycle.** RD cells (5x10^5 cells/well) were cultured in 6 wells plates for 24 h. Subsequently, 4 µM PAB or control medium was added to the cells for 0, 12, 24, or 48 h, respectively. Then RD cells were harvested and rinsed with PBS. The cell pellets were fixed in 70% ethanol at 4°C overnight. Following washing twice with PBS, the cells were stained with 1.0-ml solution containing 50 mg/l PI, 1 g/l RNase A and 0.1% Triton X-100 in 3.8 mM sodium citrate on ice in the dark for 30 min. The cell cycle distribution was analyzed by BD CellQuest Pro software version 5.1 (BD Biosciences) in BD FACSCalibur flow cytometer (Becton Dickinson and Company). The histograms were analyzed using ModFit LT version 3.0 software (Verity Software House Inc.) to determine the percentage of cells in each phase of the cell cycle.

**MDC staining.** The fluorescent compound MDC has been proposed as a tracer for autophagic vacuoles (6-8). RD cells (2x10^5 cells/well) were cultured in 6 wells plates for 24 h. 24 h later, RD cells were treated with 4 µM PAB for another 24 h and incubated with 0.05 mM MDC at 37°C for 1 h. Following incubation, the cells were washed once with PBS. Intracellular MDC in three fields was measured by fluorescence microscopy at an excitation wavelength of 380 nm and an emission wavelength of 525 nm (Leica Microsystems, Inc.; magnification, x200).

**3-MA treatment.** The RD cells were treated with PAB (4 µM) together/or 3-MA (2 mM) for 24 h.

**Western blot analysis of total cytoplasmic and nuclear protein expression.** RD cells (1x10^5 cells/well) were cultured in a 25-ml culture bottle for 24 h and subsequently treated with 4 µM PAB for 24 h. Adherent and floating cells were collected and frozen at -80°C. Western blot analysis was performed for the determination of the total protein expression as previously described (4). Briefly, protein (40 µg/lane) was loaded in 10% SDS-PAGE and transferred onto nitrocellulose membrane. The membranes were blocked for 1 h at room temperature in blocking buffer [5% nonfat dry milk in 1X TBST (Tris-HCL 1.576 g/l, NaCl 8.00 g/l, Tween-20 0.1%)]. Then the membranes were incubated with primary polyclonal antibody (1:1,000) including caspase-8 (cat. no. 66093-1-Ig; ProteinTech Group, Inc.), caspase-9 (cat. no. 66169-1-Ig; ProteinTech Group, Inc.), cyclin B1 (cat. no. 55004-1-AP; ProteinTech Group, Inc.), Beclin 1 (cat. no. 11306-1-AP; ProteinTech Group Inc.), LC3 (cat. no. 14600-1-AP; ProteinTech Group, Inc.), β-actin (cat. no. 66099-1-Ig; ProteinTech Group, Inc.) and tubulin (cat. no. 10068-1-AP; ProteinTech Group, Inc.), or phosphorylated H2A histone family member X (γ-H2AX; cat. no. 97188; Cell Signaling Technology, Inc.) at 4°C overnight, washed three times for 5 min each with TBST and incubated with the appropriate secondary polyclonal antibody (1:2,000) including Alkaline Phosphatase AffiniPure Goat Anti-Mouse IgG (H+L) (cat. no. 115-055-003; Jackson ImmunoResearch Laboratories, Inc.), Alkaline Phosphatase AffiniPure Goat Anti-Rabbit IgG (H+L) (cat. no. 111-055-003; Jackson ImmunoResearch Laboratories, Inc.), HRP-conjugated AffiniPure Goat Anti-Mouse IgG (H+L) (cat. no. SA00001-1; ProteinTechGroup, Inc.) or HRP-conjugated AffiniPure Goat Anti-Rabbit IgG (H+L) (cat. no. SA00001-2; ProteinTech Group, Inc.) at room temperature for 1 h. The loading control used was tubulin or actin. The proteins were visualized using NBT and BCIP for the AP-conjugated secondary antibody for Fig. 5 and the data was collected by Canon Scan (9000F MarkII; Canon); and using the ECL kit for the HRP-conjugated secondary antibody for Fig. 6 and the data was collected by Azure C500 (Azure Biosystems).

**Statistical analysis.** All experiments were performed independently ≥3 times, and the data are presented as the mean ± SD. Statistical analysis was performed using SPSS 10.0 software (SPSS, Inc.). Differences between two groups at various timepoints were assessed using one-way repeated measures ANOVA. Differences among multiple groups were assessed using one-way ANOVA with Tukey’s post hoc test. P<0.05 was considered to indicate a statistically significant difference.

**Results**

**PAB inhibits RD cell proliferation.** In the present study, the inhibitory role of PAB was investigated in human rhabdomyosarcoma RD cells. The results of the MTT assay demonstrated that 1-20 µM PAB inhibited cell proliferation, and between 12 and 48 h, the inhibitory ability of PAB increased (Fig. 1). At 36 h, the IC_{50} was estimated to be 41 µM, and at 48 h, the IC_{50} was 7.5 µM. At 48 h, 4 µM of PAB inhibited RD cell proliferation with an inhibitory ratio of 35% (Fig. 1). These results were consistent with previous studies (4,5); therefore, 4 µM PAB was selected for subsequent experiments.

**PAB alters tubulin distribution.** PAB has been reported to target tubulin (20,21). Therefore, the current study investigated the effects of PAB on the microtubule networks of RD cells by tubulin immunofluorescence staining. Treatment of RD cells with 4 µM PAB for 24 h resulted in the aggregation of microtubules (Fig. 2). To verify the
location of the aggregation of the microtubule fibers, the cell nuclei were stained, and the results demonstrated that the fibers were located in the cytoplasm (Fig. 2). At the same time, it was noted that cells became larger and nuclei became larger in PAB-treated group, which was consistent with a previous study (22), so it was speculated that PAB resulted in the aggregation of the microtubule fibers, and cells could not divide although DNA replication had been completed.

**PAB inhibits cell migration.** The effects of PAB on RD cell migration were assessed by wound healing assay. The results demonstrated that RD cells migrated over time (from 0 to 36 h), since the edge of the wound gradually disappeared, which was consistent with the effects noted in the aggregation of microtubule fibers. However, following PAB treatment, the edge of the wound was visible by morphological observation at 12, 24 and 36 h post-treatment (Fig. 3). Therefore, these results indicated that PAB inhibited RD cell migration.

**PAB induces apoptosis.** To further determine whether PAB induced apoptosis in RD cells, cell morphology was assessed. At 24 and 48 h, the induction of apoptosis was evident in PAB-treated cells compared with that in the cells that had undergone control treatment; apoptotic bodies and condensed cells were observed in the PAB-treated cells (Fig. 4A). In addition, in the agarose gel electrophoresis assay, no DNA ladder was present at 0 h, whereas the appearance of the DNA ladder was noted at 24, 36 and 48 h following PAB treatment (Fig. 4B). Following 24 h post-PAB treatment, the expression levels of pro-caspase-9 appeared to be decreased, whereas those of active caspase 8 appeared to be increased compared with the control group (Fig. 4C). Although PAB changed the tubulin aggregation, PAB did not affect tubulin expression, and the expression of tubulin was same as actin and histone (data not shown). These results suggested that PAB induced apoptosis in RD cells.

**PAB induces G2/M cell cycle arrest.** To investigate the mechanism of cell proliferation inhibition mediated by PAB, flow cytometry was used for cell cycle analysis. Following 4 µM PAB treatment for 12, 24, 36 or 48 h, the cell number of tetraploid cells was increased compared with that in the control
group (Fig. 5A and B), indicating that the PAB-treated cells were arrested at the G2/M phase. Western blot analysis results demonstrated that PAB treatment upregulated the expression levels of γ-H2AX and cyclin B1 at 24 h post-treatment (Fig. 5C). Therefore, PAB induced cell cycle arrest, which was likely in the M phase.
To further confirm the role of PAB in inhibiting cell proliferation, the current study examined whether PAB induced autophagy in RB cells. The results demonstrated that 4 µM PAB increased the MDC-positive points, which are considered to be markers of autophagy (6,7) (Fig. 6A). The present study further demonstrated that at 24 h, the expression levels of autophagy markers beclin 1 and LC3 were increased in RB cells treated with PAB compared with those in the control group (Fig. 6B). In the presence of the autophagy inhibitor 3-MA (2 mM), an increased proliferation inhibition ratio was observed in PAB-treated cells compared with control treatment (Fig. 6C), and comparing to PAB treatment group, the expression level of beclin 1 was decreased in PAB together with 3-MA treatment group, and LC3 had a decreased trend (Fig. 6D). Therefore, inhibiting autophagy promotes cell death in PAB-treated RD cells.

Discussion

PAB exhibits potent antitumor effects on human breast cancer MCF-7, cervical cancer HeLa and melanoma A375 cells by inducing apoptosis (1-5), and on murine fibrosarcoma L929, human thyroid squamous cell carcinoma SW579 cells and human lung fibroblasts MRC5 by inducing autophagy (6-8). In the present study, the effects of PAB were examined on human rhabdomyosarcoma RD cell proliferation. The present study provided novel information that may aid further translation of new candidate drugs into improved clinical treatments.

The results of the present study demonstrated that PAB inhibited RD cell proliferation. PAB inhibits the proliferation of several types of cancer cells, and the present study broadens the antineoplastic spectrum of PAB through confirming PAB inhibiting Rhabdomyosarcoma RD cell growth and cell migration and inducing apoptosis and cell cycle arrest.

Previous studies have demonstrated that PAB induces apoptosis alone (1-5), apoptosis and autophagy (22) or autophagy alone (6-8) to exert its inhibitory role in tumor cells. The results of the present study confirmed that PAB induced apoptosis in RD cells, which was consistent with the data reported in previous studies (1-5). In addition, in the present study, apoptosis was accompanied by autophagy, which was consistent with the results of a previous study in human breast cancer MCF-7 cells (22). Currently, the mechanism by which PAB induces apoptosis or autophagy in specific types of cells is unknown. It was speculated that different apoptotic or autophagic factors may determine the cell fate following PAB treatment. Different apoptotic or autophagic factors will be investigated in future studies.

PAB has been reported to exert its antitumor effects via disrupting tubulin function (20). The ability of PAB to disrupt tubulin formation in RD cells was examined in the present study, and the results demonstrated that PAB treatment resulted in the aggregation of microtubule fibers, which was consistent with a previous study (20). Human rhabdomyosarcoma can spread locally, regionally or distantly, depending on the aggressiveness of the tumor cells (9). In the present study PAB treatment appeared to inhibit cell migration. In addition, PAB induced cell cycle arrest at the G2/M phase following 12-h treatment, whereas the expression levels of γ-H2AX and cyclin B1 were upregulated at 24 h post-treatment compared
with those in the control group. These results suggested that PAB induced M phase arrest. Therefore, PAB exerted its antitumor effects through multiple mechanisms of action.

In conclusion, the results of the present study demonstrated that PAB exerted its antitumor roles by inducing apoptosis, autophagy and cell cycle arrest in human rhabdomyosarcoma RD cells. Therefore, PAB may be considered a potential treatment agent for human rhabdomyosarcoma.

Acknowledgements

Not applicable.

Funding

This work was supported by the National Natural Science Foundation of China (grant nos. 81871634 and 81301416), the Postdoctoral Science Foundation of China (grant nos. 2014M561302 and 2015T80299), the Norman Bethune Program of Jilin University (grant no. 2015202), the Jilin Provincial Science and Technology Department (grant nos. 20140204004Y, 20160414025GH and 20190304064Y) and the Department of Human Resources and Social Security of Jilin Province (grant no. 2016014).

Availability of data and materials

All data generated or analyzed during the study are included in this published article.

Authors' contributions

JY, CL and FW designed the experiments; BW, TW, YW, WH performed the experiments; JY, CL, FW, BW, TW, YW, WH, SZ, YS, JL and YL analyzed the data. All authors have read and approved the manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Pan DJ, Li ZL, Hu CQ, Chen K, Chang JJ and Lee KH: The cytotoxic principles of Pseudolarix kaempferi: Pseudolaric acid-A and -B and related derivatives. Planta Med 56: 383-385, 1990.
2. Gong XF, Wang MW, Tashiro S, Onodera S and Ikejima T: Pseudolaric acid B induces apoptosis through p53 and Bax-Bcl-2 pathways in human melanoma A375-S2 cells. Arch Pharm Res 28: 68-72, 2005.
3. Gong X, Wang M, Tashiro S, Onodera S and Ikejima T: Involvement of JNK-initiated p53 accumulation and phosphorylation of p53 in pseudolaric acid B induced cell death. Exp Mol Med 38: 428-434, 2006.
4. Yu JH, Cui Q, Jiang YY, Yang W, Tashiho S, Onodera S and Ikejima T: Pseudolaric acid B induces apoptosis, senescence, and mitotic arrest in human breast cancer MCF-7. Acta Pharmacol Sin 28: 1975-1983, 2007.
5. Yu JH, Wang HJ, Li X, Tashiho S, Onodera S and Ikejima T: Protein tyrosine kinase, JNK, and ERK involvement in pseudolaric acid B-induced apoptosis of human breast cancer MCF-7 cells. Acta Pharmacol Sin 29: 1069-1076, 2008.
6. Yu J, Li X, Tashiho S, Onodera S and Ikejima T: Bcl-2 family proteins were involved in pseudolaric acid B-induced autophagy in murine fibrosarcoma L929 cells. J Pharmacol Sci 107: 295-302, 2008.
7. Yu J, Ren P, Zhong T, Wang Y, Yan M, Xue B, Li R, Dai C, Liu C, Chen G and Yu XF: Pseudolaric acid B inhibits proliferation in SW579 human thyroid squamous cell carcinoma. Mol Med Rep 12: 7195-7202, 2015.
8. Wang Y, Gao H, Wu T, Wang Z, Song F, Chen A, Zhang J, Zhang W, Zhang H and Yu J: Pseudolaric acid B induced autophagy, but not apoptosis, in MRC5 human fibroblast cells. Onco Lett 15: 863-870, 2018.
9. Dzialba I, Kurzawa P, Dopiera1 L, Jaruzelikiewicz‑Lewandowska D: Rhabdomyosarcoma in children-current pathologic and molecular classification. Pol J Pathol 69: 20-32, 2018.
10. Rabinovitch PS, Chen L, Xin L, Jovanovic I, Resau JH, Willson JK, Chen Q, Zhang L, Wang Y and Zhang N: Pseudolaric acid B induces mitotic catastrophe followed by apoptotic cell death in murine fibrosarcoma L929 cells. Eur J Pharmacol 683: 162-26, 2012.
11. Qi M, Yao G, Fan S, Cheng W, Tashiro S, Onodera S and Ikejima T: Pseudolaric acid B induces mitotic catastrophe in SW579 human thyroid squamous cell carcinoma. Acta Pharmacol Sin 35: 806-813, 2014.
12. Ahn JH, Lee YW, Ahn SK and Lee M: Oncogenic BRAF inhibitor UAI-201 induces cell cycle arrest and autophagy in BRAF mutant glioma cells. Life Sci 104: 38-46, 2014.
13. Wang R, Xiao X, Wang PY, Wang L, Guan Q, Du C and Wang XJ: Stimulation of autophagic activity in human glioma cells by anti-proliferative ardisiposilide I isolated from Ardisia pusilla. Life Sci 110: 15-22, 2014.
14. Li Z, Yu J, Liu L, Wei Z, Ehrlich ES, Liu G, Li J, Liu X, Wang H, Yu XF and Zhang H: Coxsackievirus A16 infection induces neural cell and non-neural cell apoptosis in vitro. PLoS One 9: e111174, 2014.
15. Lee YJ, Won AJ, Lee J, Jung JH, Yoon S, Lee BM and Kim HS: Molecular mechanism of SAHA on regulation of autophagic cell death in tamoxifen-resistant MCF-7 breast cancer cells. Int J Med Sci 9: 881-893, 2012.
16. Lee YZ, Yang CW, Chang HY, Hsu HY, Chen IS, Chang HS, Lee CH, Lee JC, Kumar CR, Qiou YQ, et al: Discovery of selective inhibitors of Glutaminase-2, which inhibit mTORC1, activate autophagy and inhibit proliferation in cancer cells. Oncotarget 5: 6087-6101, 2014.
17. He H, Feng YS, Zang LH, Liu WW, Ding LQ, Chen LX, Kang N, Hayashi T, Tashiro S, Onodera S, et al: Nitric oxide induces apoptosis and autophagy; autophagy down-regulates NO synthesis in physalin A-treated A375-S2 human melanoma cells. Food Chem Toxicol 71: 128-135, 2014.
18. Han Y, Yang YN, Yuan HH, Zhang TT, Sui H, Wei XL, Liu L, Huang P, Zhang WJ and Bai XY: UC01, a long non-coding RNA up-regulated in colorectal cancer influences cell proliferation, apoptosis and cell cycle distribution. Pathology 46: 396-401, 2014.
19. Lee H, Chin H, Kim K and Lee D: ERBB3 knockdown induces cell cycle arrest and activation of Bak and Bax-dependent apoptosis in colon cancer cells. Oncotarget 5: 5138-5152, 2014.
20. Wong VK, Chiu P, Chung SS, Chow LM, Zhao YZ, Yang BB and Ko BC: Pseudolaric acid B, a novel microtubule-destabilizing agent that circumvents multidrug resistance phenotype and exhibits antitumor activity in vivo. Clin Cancer Res 11: 6002-6101, 2005.
21. Song F, Yu X, Zhang H, Wang Z, Wang Y, Meng X and Yu J: Pseudolaric acid B inhibits neuroglioma cell proliferation through DNA damage response. Oncol Rep 38: 2211-2218, 2017.
22. Yu J, Chen C, Xu T, Yan M, Xue B, Wang Y, Liu C, Zhong T, Wang Z, Meng X, et al: Pseudolaric acid B activates autophagy in MCF-7 human breast cancer cells to prevent cell death. Oncol Lett 11: 1731-1736, 2016.